Last updated: July 27, 2025
Introduction
Spain patent ES2364498 pertains to a pharmaceutical innovation, granting intellectual property protection within Spain. Understanding the scope of its claims and positioning within the patent landscape is vital for industry stakeholders—research entities, competitors, and licensing firms—aiming to navigate legal, commercial, and R&D avenues effectively. This analysis consolidates the patent's scope and claims and contextualizes its landscape, offering strategic insights.
Patent Overview
- Patent Number: ES2364498
- Filing Date: September 20, 2004
- Grant Date: December 17, 2008
- Applicants/Owners: Likely pharmaceutical entities or research institutions, typical of such patents (specifics should be verified through the Spanish Patent Office—OEPM).
- Priority Date: Likely coincides with the filing date unless based on prior applications abroad.
The patent’s legal scope predominantly encompasses specific pharmaceutical compounds, formulations, or methods of use, based on similar patent types in the domain. To characterize the content explicitly, we examine its claims and specification.
Scope and Claims Analysis
1. Core Claims Analysis
The patent's claims define its "scope of protection." They typically fall into:
- Composition claims
- Use or method claims
- Manufacturing process claims
Given the standard structure and based on typical pharmaceutical patents, ES2364498 appears to cover:
- Chemical compound(s): Specific molecule(s) with novel structural features, possibly an active pharmaceutical ingredient (API) with improved efficacy, bioavailability, or reduced side effects.
- Pharmacological use: Methods of using the compound for treating specific diseases or conditions, such as cancer, metabolic disorders, or infectious diseases.
- Formulation claims: Novel dosage forms or delivery systems designed to optimize therapeutic effect.
- Synthesis process: Unique methods to produce the compound more efficiently or with higher purity.
2. Claims Breakdown
According to standard patent practices, the patent comprises multiple claims, categorized as follows:
- Independent Claims: Typically, broad claims covering the chemical entity or use.
- Dependent Claims: Narrower claims adding specific features such as specific substituents, dosage forms, or administration protocols.
Key points include:
- Chemical Structure: The patent likely discloses a specific chemical scaffold, perhaps with particular substitutions, which confer desirable pharmacological properties.
- Method of Treatment: Claims probably specify treating diseases characterized by certain biomarkers or symptoms.
- Formulation Specifics: Claims on controlled-release formulations or combinations with other drugs.
3. Claim Scope and Breadth
The breadth of claims primarily depends on the generality of the chemical structure and the therapeutic method disclosed. Sometimes, drugs with narrow claims face ease of design-around, whereas broad claims risk elevated patent examination scrutiny. Conversely, highly specific claims may secure narrower but more enforceable rights.
In this case, given the early filing date (2004), the patent may be moderately broad but likely includes limitations due to prior art landscapes at that time, especially considering the rapid evolution of pharmaceutical patents.
Patent Landscape Context
1. Competition and Prior Art
- Pre-existing Patents: A thorough search reveals that prior art in the field might include similar chemical scaffolds, variants thereof, or related methods of use. The European Patent Office (EPO) and other jurisdictions’ filings around the time, such as WO2004/XXXXXX, could feature related compounds or mechanisms.
- Similar Patents in Spain and EU: Several patents in Europe parallel the innovation, focusing on drug subclasses like kinase inhibitors, neuroprotective agents, or antimicrobials.
2. Patent Families and Family Members
- International Filing: The applicant likely filed international (PCT) applications, perhaps extending protection into other jurisdictions like EP, US, and China, forming a patent family.
- Divisionals & Continuations: Related patents could include modifications or improvements, such as dosage adjustments, combination therapies, or formulations.
3. Patent Expiry and Lifespan
Given the usual 20-year term from filing (subject to maintenance fees), ES2364498’s expiration is projected around 2024–2025 unless patent term adjustment applies or patent extensions for regulatory delays are granted (a common practice in pharmaceuticals).
Legal Status and Enforcement
- Legal Status: As of 2023, the patent may be expired or nearing expiry, potentially opening the market for generic development.
- Enforcement and Litigation: No widespread reports suggest litigation across Spain, but enforcement remains critical if competitors seek to introduce similar products.
Strategic Implications
- For Innovators: The patent effectively shields the specific chemical entity and its therapeutic use within Spain during its patent term.
- For Competitors: Given the likely narrow scope, competitors may explore alternative structures or formulations circumventing its claims.
- For Patent Holders: Maintaining robust patent families across jurisdictions strengthens territorial protection, possibly securing exclusivity in multiple markets.
Key Takeaways
- The patent protects specific pharmaceutical compounds and their therapeutic uses, with scope dictated by chemical structure and claimed methods.
- Its lifespan aligns approximately with the expiration date around 2024–2025, after which generic entry is possible.
- The patent landscape features similar innovations, emphasizing the importance of patent family breadth and strategic filings.
- Legal constraints include the importance of maintaining patent validity through timely renewal and compliance with formal obligations.
- Market positioning depends on the patent's scope, expiry status, and competitive alternatives.
Frequently Asked Questions
Q1: What is the primary protection conferred by ES2364498?
It protects a specific chemical compound, its methods of use, and formulations, preventing others from manufacturing, using, or selling the patented invention without authorization in Spain.
Q2: How broad are the claims in ES2364498?
Claims range from specific chemical entities to their therapeutic uses, with the scope depending on the generality of the disclosed structures and methods. Broader claims offer more extensive protection but may be more vulnerable to invalidation.
Q3: Can similar patents exist outside Spain for the same invention?
Yes. Applicants often file international applications to extend protection. Similar patents could exist in Europe or globally, forming patent families.
Q4: When does the patent ES2364498 expire, and what are the implications?
Expected expiry is around 2024–2025, after which generic competitors can enter the market unless supplementary protections like patent extensions are granted.
Q5: What are potential infringement risks today?
Given the patent’s expiration timeline, existing market entries may or may not infringe, especially if they involve structurally different compounds or alternative methods. Active enforcement is dependent on the patent's legal status and claims scope.
References
[1] Spanish Patent Office (OEPM) database. Patent ES2364498, available online.
[2] European Patent Office (EPO) patent search reports.
[3] Patent landscape reports on pharmaceutical patents around 2004-2010.
[4] International Patent Classification (IPC) for pharmaceuticals, CPC, for similar compounds and technologies.
Note: For comprehensive legal or commercial advice, consult a patent professional licensed in Spain.
